Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

ARGENX SE (ARGX)

As of 2026-11-17 · 10/15 boxes filled from SEC filings and market data

Report price $947.52 (close 2026-11-17); latest close $925.70 (2026-11-20), -2.3% since the report; figures re-marked at the latest close

Conclusion: PASS

Conviction low · base case none · downside -51% · upside +18%

The market is paying 51.0x FY2025 EV/EBITDA and 81.2x FY2025 EV/FCF for a single-molecule franchise with real operating momentum, a price that already discounts years of above-peer growth. Holding those multiples requires EBITDA growth well above what the peer group delivers, or the multiple converging toward their range. PASS: the business is excellent, but at $947.52 the valuation leaves no margin of safety, and neither tail is favourable enough on its own to justify a directional position. There is no base case, because the peers' multiple is a GAAP P/E while the company's GAAP P/E of 45.4x sits more than 5% from the operating, tax-normalized 70.7x that the downside is struck on, so no comparable peer multiple sets one. The downside is $455.83, -51.9%, on -25.0% earnings at a compressed P/E of 45.35x (today 70.7x). The upside is $1,089.65, +15.0%, on +15% earnings at today's P/E of 70.7x.

Key numbers

  • Share price: $925.70
  • Market cap: $57.29B
  • Latest financial period: TTM to Dec 31, 2025
  • EV / EBITDA (FY Dec 2025): 49.8x
  • P/E (FY Dec 2025): 44.4x
  • FCF yield: 1.2%
  • Price / book: 7.83x
  • Earnings-quality flags (FY Dec 2025): Income tax benefit on a pre-tax profit (e.g. a valuation allowance release), against a 21% charge $281.9M (22% of net income)
  • P/E, adjusted (FY Dec 2025): 56.7x
  • P/E, operating (tax-normalized) (FY Dec 2025): 69.1x
  • EV / FCF (FY Dec 2025): 79.2x
  • ROIC (FY Dec 2025): 21.5%
  • WACC: 5.8%
  • Economic profit spread: +15.7 pts
  • EV / EBITDA sanity: 1

The 15 boxes

  1. ✓ 1. Long-form business notes

    argenx has flipped from a pre-revenue clinical-stage antibody company (FY2020 20-F: 'clinical-stage biotechnology company', efgartigimod BLA filed December 2020, PDUFA 17 December 2021) into a single-product commercial company: VYVGART/VYVGART HYTRULO product net sales of $4.2 billion in FY2025, with research & development of $1.4 billion and 1,863 full-time employees at 31 December 2025. The revenue line is cyclical in the extreme — $497.3M in FY2021, $10.0M in FY2022, $35.5M in FY2023 — because those years were collaboration/licence income, not product sales; operating income swung from -$720.3M in FY2022 to +$1.05B in FY2025 and operating cash flow from -$862.8M in FY2022 to +$685.2M in FY2025. The earnings path also contains non-operating items (FY2024 net income of $833.0M against pre-tax income of $85.2M and operating income of -$21.7M; $99.8M and $105.7M of intangible amortization in FY2022 and FY2023), so normalized operating earnings, not the reported bottom line, are the right base.

  2. ○ 2. Competitive advantage

    The advantage is a licence, not a brand: VYVGART's U.S. base regulatory exclusivity is expected to run to December 2033 and EU protection to August 2032, and that one molecule is the entire commercial franchise (gMG, CIDP, ITP in Japan only). FY2025 shows the model is highly cash-generative and asset-light once approved — operating income $1.05B, operating cash flow $685.2M against capex of $6.2M — but FY2022 shows the same operating leverage in reverse, with revenue collapsing to $10.0M and operating cash flow of -$862.8M. Against that stand named big-pharma competitors, an explicit biosimilar pathway and IRA/MFN pricing pressure; the six-year XBRL table shows no revenue for FY2024 or FY2025, so margins on the current base cannot be computed from these sources.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 VYVGART product net sales were $1.721 billion, up 54% year over year and 13% sequentially, with nine-month 2026 product net sales of $4.534 billion versus $2.866 billion in nine months 2025. Q3 2026 operating profit was $486 million and profit for the period was $506 million; SG&A included about $150 million of Forte acquisition-related expenses. Cash, cash equivalents and current financial assets were $3.7 billion at September 30, 2026 after about $2.1 billion paid for Forte, net of acquired cash. FY2026 combined R&D and SG&A expense guidance is about $4 billion including Forte costs.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ○ 9. Insider trading interpretation
  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans